The ATPAF1 Knockout HT29 Polyclonal Cells are a heterogeneous population of HT29 colon adenocarcinoma cells engineered via CRISPR/Cas9-mediated disruption of the ATPAF1 gene. This polyclonal knockout model provides a robust loss-of-function system for investigating mitochondrial respiratory chain assembly and cellular energy metabolism. The CRISPR/Cas9 editing introduces targeted gene disruptions across the population, generating diverse ATPAF1-inactivating alleles without clonal selection, thus preserving genetic heterogeneity and minimizing clonal artifacts.
The HT29 parental cell line was established from a primary colorectal adenocarcinoma in a Caucasian female and serves as a well-characterized model for colorectal cancer. These epithelial cells exhibit adherent growth, tight junction formation, and polarization, making them suitable for studies of intestinal barrier function, carcinogenesis, and drug transport. Their relevance to colorectal cancer research provides a disease-relevant context for examining mitochondrial dysfunction.
ATPAF1 encodes an essential assembly factor for the mitochondrial F?F? ATP synthase. Regulated by AMPK, PGC-1??, and NRF1, ATPAF1 interacts with ATP synthase subunits ATP5A1 and ATP5B and mitochondrial chaperones to assemble functional Complex V. This process is critical for coupling the electron transport chain to ATP production and maintaining mitochondrial membrane potential. Disruption of ATPAF1 halts Complex V assembly, impairs oxidative phosphorylation, and compels cells to upregulate glycolytic pathways, mimicking cancer-associated metabolic reprogramming.
In HT29 colorectal cancer cells, ATPAF1 knockout creates a model of mitochondrial dysfunction that recapitulates aspects of Complex V deficiency, lactic acidosis, and hypertrophic cardiomyopathy at the cellular level. The loss forces a shift toward aerobic glycolysis, enabling study of metabolic adaptation, tumor cell survival under energetic stress, and the role of mitochondrial biogenesis regulators. This model also facilitates investigation of how ATP synthase disruption influences chemosensitivity and drug resistance in colon cancer.
This polyclonal knockout model supports assays such as Seahorse respirometry, ATP luminescence, Western blotting for ATP synthase subunits, and mitochondrial membrane potential measurement with TMRE or JC-1. It is applicable to metabolic reprogramming research, drug resistance studies, and screening of mitochondria-targeted compounds. For further information, contact Ascent Research.
